IL2 and neoplasm: Later, scholars noted that low dose of IL-2 can enhance the cytotoxicity of immunocyte and the efficacy of anti-tumor drugs, including hRS7, hI-con1, herceptin, adecatumumab, trastuzumab and pertuzumab (125–129) in USPC patients.